COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04533399

Shabir A Madhi, MBBCH, PhD

Rani Naidoo, premadevi.naidoo@ppdi.com (PI email not reported)

2020-08-31

Completed

RCT

Randomized

Sequential assignment

Blind label

multi-center

Prevention

inclusion criteria: all subjects: adult male and female aged ≥ 18 to < 65 years at screening for cohorts 1 and 2 and adult male or female aged ≥ 65 to < 85 years at screening for cohort 1 only. body mass index (bmi) of 17 to 40 kg/m². provides informed consent prior to study participation and is willing to comply with study procedures, including potential home visits. women of child-bearing potential must agree not to have sexual intercourse with men, or must consistently use an agreed method of contraception from at least 21 days prior to enrolment in the study, through 6 months after the last vaccination. hiv-negative subjects only: documentation of hiv-negative test result by a method approved in south africa. healthy at study screening, as determined by the investigator. hiv-positive subjects only: documentation of hiv-positive test result by a method approved in south africa. receiving highly active antiretroviral therapy (haart) and has been using the same regimen for at least 8 weeks before screening. changes in antiretroviral dosage within 8 weeks of entering the study are allowed, as are exchanges in pharmacological formulations. medically stable at screening, as determined by the investigator, and free of opportunistic infections in the 1 year prior to first study vaccination. have a hiv-1 viral load < 1000 copies/ml within 45 days of randomization in the study.

any current acute illness requiring medical or surgical care, or chronic illness (excluding hiv in hiv-positive subjects) that requires changes in medication in the past 2 months indicating that chronic illness/disease is not stable. chronic disease, including: hypertension (elevated blood pressure [bp]) ≥ grade 2 (systolic bp ≥ 160 mmhg; and/or diastolic bp ≥ 100 mmhg) according to the south african hypertension society's practice guidelines. note: hypertension [elevated bp] ≤ grade 1 (systolic bp ≤ 159 mmhg; diastolic bp ≤ 99 mmhg) according to the south african hypertension society's practice guidelines is not exclusionary; congestive heart failure with a history of an acute exacerbation of any severity in the prior 2 years; chronic obstructive pulmonary disease (copd) with a history of an acute exacerbation of any severity in the past 2 years; evidence of unstable coronary artery disease in the past 3 months, as determined by the investigator; note: stable coronary heart disease is not exclusionary. asthma requiring regular/chronic control medication (eg, short-acting beta2-agonist [saba] > 2 days per week; or any chronic use of inhaled corticosteroids [ics], long-acting beta2-agonist [laba], leukotriene receptor antagonist [ltra], or oral corticosteroids), and/or worsening of asthma symptoms in the past 3 months; note: asthma not requiring regular/chronic control medication, and not requiring saba > 2 days per week, and not demonstrating worsening of symptoms in the past 3 months, will not be excluded. type 1 or 2 diabetes (adult onset) requiring treatment with insulin; note: non-insulin dependent type 2 diabetes is not exclusionary. chronic kidney disease/renal insufficiency; chronic gastrointestinal and hepatic diseases; chronic neurological diseases (such as multiple sclerosis, dementia, transient ischemic attacks, parkinson's disease, degenerative neurological conditions, neuropathy, or epilepsy), or a history of stroke within 12 months with residual symptoms, or previous neurological disorder within 12 months with residual symptoms; note: history of migraine or chronic headaches, or nerve root compression that have been stable on treatment for the last 4 weeks are not exclusionary. participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination. prior receipt of investigational or approved covid-19 vaccine at any time. history of a diagnosis of suspected or confirmed covid-19. received influenza (flu) vaccination within 14 days prior to first study vaccination; or any other vaccine within 4 weeks prior to first study vaccination; or planned vaccination with 5 weeks after first study vaccination. any autoimmune or immunodeficiency disease/condition (excluding hiv in hiv-positive patients). chronic (more than 14 days continuous) administration of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 90 days prior to first study vaccination (excluding haart in hiv-positive subjects). note: an immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. the use of topical, inhaled, and nasal glucocorticoids will be permitted. received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination (excluding haart in hiv-positive subjects). acute respiratory and/or non-respiratory illness consistent with potential covid-19, concurrent with or within 14 days prior to first study vaccination, or documented temperature of > 38°c during this period. known blood clotting disorder. active cancer (malignancy) within 3 years prior to first study vaccination (with the exception of adequately treated non-melanoma skin cancers, as assessed by the investigator). any known allergies to products contained in the investigational product, or latex allergy, or any history of anaphylaxis in relation to any previous vaccination. women who are breastfeeding or who are pregnant at the time of screening, or plan to become pregnant within the first 6 months of the study. history of alcohol abuse or drug addiction within 2 years prior to the first study vaccination. any condition (other than hiv in hiv-positive subjects) that, in the opinion of the investigator, would pose a health risk to the subject if they participate in the study, or could interfere with evaluation of the study vaccine or interpretation of study results. study team member or first-degree relative of any study member. other protocol-defined inclusion/exclusion criteria may apply

3

Novavax

18

84

South Africa

Healthy volunteers

N/A

4422

Cohort 1: HIV- Participants with Solicited Adverse Events (AEs);Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 1: HIV- Participants with Unsolicited AEs;Cohort 2: HIV+ Participants with Solicited AEs;Cohort 2: HIV + Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 2: HIV+ Participants with Unsolicited AEs;Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs);Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs);Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs);Healthcare Worker Expansion (Cohort 3): Participants with AESI's;Healthcare Worker Expansion (Cohort 4): Participants with AESI's

None

Phase 2

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "5 \u03bcg (+ 50 \u03bcg);2;day0-21; HIV negative", "treatment_id": 1158, "treatment_name": "Sars-cov-2 rs/matrix-m1 adjuvant", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u03bcg (+ 50 \u03bcg);2;day0-21; HIV positive", "treatment_id": 1158, "treatment_name": "Sars-cov-2 rs/matrix-m1 adjuvant", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]